TUCSON,
Ariz., Aug. 16,
2012 /PRNewswire/ -- After a competitive
multi-state process, Accelr8 Technology Corporation (NYSE MKT: AXK)
today announces that it is moving its headquarters from
Denver, CO to Tucson, AZ.
Founded in 1982, Accelr8 develops instruments used
for the detection of pathogenic microorganisms. Its BACcelâ„¢ rapid
diagnostic system, in development, is the first technology that is
able to count and identify dangerous pathogens and their drug
resistance expression within the same day of obtaining a patient
specimen, instead of the two to three days required for standard
methods. This speed allows for a significant improvement in the
treatment of the over 1.7 million people in the US who contract a
hospital acquired infection each year, and access to a
multi-billion dollar market.
Accelr8 has selected Tucson as best meeting its needs for future
high-growth plans. Accelr8 will bring high-skilled, high-wage
jobs to Southern Arizona with
plans to fill 65 positions over the next three years and the
potential to grow to 200-300 employees in subsequent years.
Headquarter positions include engineers, scientists,
sales/marketing, management, finance, quality/regulatory and
manufacturing. The company will occupy approximately 15,000 square
feet of space in Pima County's
Herbert K. Abrams Public Health Center at 3950 S. Country Club
Road. After a build out of wet lab space, the company is expected
to be operational by early 2013.
"Accelr8 is developing a revolutionary product in
the diagnostics area and we were impressed with the region's
emerging bioscience strength, innovation and support that can help
ensure our future success," said Lawrence
Mehren, president and CEO, Accelr8 Technology
Corporation.
"Accelr8 strengthens the biotechnology excellence
our state has been building, while creating high-quality jobs for
Arizonans," said Governor Jan
Brewer. "I am grateful to the Arizona Commerce Authority,
TREO and other regional partners whose excellence and creativity
produced infrastructure solutions to secure Accelr8 for
Arizona."
"We're thrilled to attract a publicly-traded
headquarters in a key, targeted industry," said Joe Snell, president & CEO, TREO. "Accelr8
represents another building block as we emerge as a leading biotech
hub."
About Accelr8
Accelr8 Technology Corporation is a developer of
innovative materials and instrumentation for advanced applications
in medical instrumentation, basic research, drug discovery, and
bio-detection. Accelr8 is developing a rapid analytical platform
for infectious pathogens, the BACcelâ„¢ system, based on
its innovative assay processing and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8's own
products. To learn more, visit
www.accelr8.com.
Certain statements in this news release may be
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Statements regarding
future prospects and developments are based upon current
expectations and involve certain risks and uncertainties that could
cause actual results and developments to differ materially from the
forward-looking statement, including those detailed in the
company's filings with the Securities and Exchange Commission.
Accelr8 does not undertake an obligation to publicly update or
revise any forward-looking statements, whether as a result of
new information or future
events.
About TREO
TREO offers a comprehensive approach of programs and
services to facilitate the creation of high-wage jobs, through the
attraction of new primary companies, the retention/expansion of
existing primary companies and increased business
creation/entrepreneurship strength within the region. Since
2005, TREO has facilitated the relocation and/or expansion of over
60 companies in the Tucson region,
representing nearly 17,000 jobs and $2.3
billion in economic impact. For more information, visit
www.treoaz.org.
SOURCE Accelr8 Technology Corporation